ADAR1 Capital Management LLC Grows Stake in Zura Bio Limited $ZURA

Key Points

• ADAR1 Capital Management LLC increased its stake in Zura Bio Limited by 34.9%, owning 4.10% of the company after acquiring 723,933 shares in the first quarter.
• Zura Bio reported earnings of ($0.17) EPS for the last quarter, surpassing analysts' expectations of ($0.19) by $0.02.
• Analysts currently hold a consensus rating of "Buy" for Zura Bio, with a consensus price target of $14.00 despite Oppenheimer and HC Wainwright lowering their price targets recently.

ADAR1 Capital Management LLC grew its position in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 34.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 2,801,184 shares of the company's stock after acquiring an additional 723,933 shares during the period. ADAR1 Capital Management LLC owned about 4.10% of Zura Bio worth $3,614,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Two Sigma Advisers LP purchased a new position in shares of Zura Bio during the 4th quarter worth approximately $32,000. ProShare Advisors LLC purchased a new position in shares of Zura Bio during the 4th quarter worth approximately $35,000. Wells Fargo & Company MN increased its position in Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after buying an additional 9,379 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Zura Bio during the 4th quarter valued at approximately $62,000. Finally, Nuveen LLC bought a new position in Zura Bio during the 1st quarter valued at approximately $76,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Trading Up 2.0%

ZURA traded up $0.04 during trading on Thursday, hitting $2.07. 176,988 shares of the company's stock traded hands, compared to its average volume of 341,096. The company's 50 day simple moving average is $1.59 and its two-hundred day simple moving average is $1.36. Zura Bio Limited has a 12-month low of $0.97 and a 12-month high of $5.07. The stock has a market capitalization of $134.59 million, a price-to-earnings ratio of -2.96 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. On average, equities analysts expect that Zura Bio Limited will post -0.65 EPS for the current year.

Analysts Set New Price Targets

ZURA has been the subject of a number of analyst reports. HC Wainwright reduced their price objective on Zura Bio from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, August 19th. Oppenheimer reduced their price objective on Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, August 15th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Zura Bio in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $14.00.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.